Dr Gil Morgan from OncoAlert gives his oncology highlights from social media for the week of August 4th - 10th, 2023.



He begins by highlighting the FDA approval of LONSURF (trifluridine/tipiracil) with bevacizumab for previously treated metastatic colorectal cancer following prior approval of single-agent LONSURF.



Dr Morgan also covers results from the KEYNOTE 671 trial of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early-stage non-small cell lung cancer.



He concludes by inviting colleagues to the 'Multidisciplinary Perspectives in Breast Cancer' conference taking place on October 6th.



Follow Dr Morgan on twitter: @OncoAlert



Follow ecancer on twitter: @ecancer